Table 1.

Demographic and clinical characteristics of discovery and validation groups.

	Discovery group (n = 96)	Validation group (n = 166)
Age (years ± s.d.)	49.8 ± 7.4	43.9 ± 12.0
Sex (% male)	51	64
Caucasian (%)/African-American (%)	60/35	53/32
Metabolic syndrome (%)	50	46
% currently smoking	50	51
Olanzapine/clozapine (%)	29	29
Quetiapine/paliperidone/risperidone (%)	38	39
Aripiprazole/ziprasidone (%)	33	32

The table depicts the mean ± s.d. or % values for the discovery and validation groups. No statistically significant differences were noted between the groups. A nonsignificant trend for more males in the validation group was observed (p = 0.08).